Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Quest to provide clinical trial lab services for Mainz Biomed CRC screening test

February 2025—Mainz Biomed announced an agreement with Quest Diagnostics to support commercialization of Mainz Biomed’s next-generation screening test for colorectal cancer, ColoAlert. Quest will provide clinical trial laboratory services for Mainz Biomed’s ReconAAsense study, a prospective clinical study that will include approximately 15,000 subjects from 150 sites across the United States to develop data supporting FDA validation of the test. Mainz Biomed will provide Quest with the option to exercise semi-exclusive rights to provide testing services based on the test kit for an 18-month period, assuming the test’s approval by the FDA.

FDA clears Werfen Aptiva APS IgG, IgM reagents

February 2025—Werfen announced FDA 510(k) clearance for the Aptiva antiphospholipid syndrome immunoglobulin G and immunoglobulin M reagents. These immunoassay reagents use Aptiva’s particle-based multianalyte technology for the semiquantitative determination of anticardiolipin and anti-beta 2 glycoprotein 1 IgG and IgM in human serum and aid in diagnosing primary and secondary APS, when used in conjunction with other laboratory and clinical findings.

StatLab, Diapath sign definitive agreement

February 2025—StatLab Medical Products announced it has reached an agreement to acquire Diapath (Martinengo, Italy), a manufacturer of histology and cytology products and equipment. The integration of Diapath, with its equipment offerings, manufacturing capabilities, and established customer base across Europe, Asia-Pacific, the Middle East, Africa, and Latin America positions StatLab to expand its market access, according to a StatLab press statement.

Verichem reference materials for acetaminophen, salicylate

February 2025—Verichem Laboratories has announced the availability of multilevel clinical reference materials intended for the calibration and calibration verification of acetaminophen and salicylate assays on a wide array of diagnostic testing systems. The materials come in a ready-to-use, liquid-stable format that incorporates the serum-like reactivity of a protein-based matrix with the gravimetric accuracy of an absolute standard. The kit contains 5.0 mL of material at six concentration levels and has a shelf life of 18 months when stored at 2° to 8°C. The product also contains ethanol and lactate to determine the calibration verification of these assays.

FDA grants breakthrough designation to Beckman Coulter Alzheimer’s test

February 2025—Beckman Coulter Diagnostics announced the FDA has granted breakthrough device designation to the Access p‑Tau217/β-Amyloid 1-42 plasma ratio. The blood test measures the ratio of phosphorylated tau protein (pTau217) to beta‑amyloid 1-42, two key biomarkers implicated in the neurodegenerative processes of Alzheimer’s disease. A blood-based IVD test that can quantify these biomarkers in plasma could provide a noninvasive, accessible, and earlier method of detecting Alzheimer’s-related pathology, potentially before clinical symptoms manifest, the company said in a statement.

Illumina updates NovaSeq X series

February 2025—Illumina announced a series of updates to its NovaSeq X series, including the NovaSeq X single-flow-cell system, a software upgrade, and new kits.

ARUP launches assay for influenza A (H5) virus

February 2025—ARUP Laboratories has launched an assay for the detection and subtyping of influenza A (H5) virus. The test will aid in the evaluation of people who may have been exposed to highly pathogenic avian influenza (HPAI) A virus, also known as H5N1 or bird flu.

OGT launches NGS SureSeq Myeloid MRD panel

February 2025—OGT announced the North American launch of its next-generation sequencing SureSeq Myeloid MRD panel. The ultra-sensitive panel enables the detection of 13 key measurable residual disease–associated biomarkers in acute myeloid leukemia. Ultralow variant detection, including for very large FLT3-ITDs, enables a stronger characterization of a sample’s current AML status. The company’s complimentary NGS analysis software, Interpret, is available on the cloud or as a local install and provides a powerful bioinformatic analysis pipeline.

Qiagen EZ2 Connect reaches milestone of more than 1,000 placements

February 2025—Qiagen announced it has reached a milestone of having more than 1,000 placements of the EZ2 Connect automated sample preparation instrument. Launched in 2021, the EZ2 Connect is designed to automate the entire process of nucleic acid purification, reducing hands-on time and increasing throughput while maintaining high precision and reproducibility. The company says the system is particularly beneficial for laboratories handling medium volumes of samples for use across a range of downstream molecular biology research applications, such as digital PCR and next-generation sequencing.

BioMérieux acquires immunoassay start-up SpinChip

February 2025—BioMérieux has entered into an agreement to acquire SpinChip Diagnostics (Oslo, Norway), a privately held company that has developed an immunoassay diagnostics platform that can deliver results from a whole blood sample within 10 minutes. SpinChip is initially developing lab-quality tests to address indications common in acute care settings, such as myocardial infarction, and will first focus on high-sensitive troponin I, NT-proBNP, and D-dimer.

MARKETPLACE

TRENDING